{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:42:33Z","timestamp":1787499753186,"version":"build-2736575974"},"reference-count":12,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJUI Compass"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the clinical significance of a second transurethral resection of the bladder tumour (TURBT) in patients with a primary high\u2010grade (HG) Ta non\u2010muscle invasive bladder cancer (NMIBC), specifically selected for the initial diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed 121 patients with primary HG Ta urothelial carcinoma treated at our institution between January 2007 and October 2024. All patients underwent an initial TURBT with the detrusor muscle present in the specimen. Patients were divided into the second TUR group (n\u2009=\u200948) and the non\u2010second TUR group (n\u2009=\u200973). Propensity score matching was performed using age, number of tumours and Bacillus Calmette\u2013Guerin treatment status. Outcomes included the residual tumour rate, recurrence\u2010free survival (RFS), time to progression to muscle invasive bladder cancer (MIBC) and cancer\u2010specific survival (CSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Residual tumour at the initial resection site was identified in four patients (8.3%) who underwent a second TUR, with two patients (4.2%) being upstaged to T1. The median follow\u2010up was 53\u2009months. There were no significant differences between the two groups in RFS (p\u2009=\u20090.60), time to progression to MIBC (p\u2009=\u20090.63) or CSS (p\u2009=\u20090.18). These findings remained consistent in the matched cohort. Multivariate analysis revealed that a second TUR was not associated with improved RFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first study to specifically address primary HG Ta bladder cancer, and it suggests that a second TUR may be omitted in selected cases, particularly when the initial resection is complete and the detrusor muscle is adequately sampled. A risk\u2010adapted approach may help reduce unnecessary procedures without compromising oncological safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bco2.70082","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:23:00Z","timestamp":1757895780000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is a second TUR necessary in patients with primary high\u2010grade Ta NMIBC, particularly in the context of initial cases?"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8612-9751","authenticated-orcid":false,"given":"Satoki","family":"Abe","sequence":"first","affiliation":[{"name":"Department of Urology, Faculty of Medicine Oita University  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujinami","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine Oita University  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine Oita University  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinro","family":"Hata","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine Oita University  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine Oita University  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadasuke","family":"Ando","sequence":"additional","affiliation":[{"name":"Organ Transplantation Promotion Project, Faculty of Medicine Oita University  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine Oita University  Yufu Oita Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwad236"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.01.011"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.5173\/ceju.2018.16832"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-025-05778-z"},{"key":"e_1_2_9_7_1","unstructured":"Babjuk M Burger M Comp\u00e9rat EMet alEAU Guidelines on Non\u2013muscle\u2010invasive Bladder Cancer (Ta T1 and CIS) \u2013 2024.https:\/\/uroweb.org\/guidelines"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2022.08.006"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"e_1_2_9_10_1","unstructured":"Japanese Urological Association.2019.Clinical practice guidelines for bladder cancer 2019 [in Japanese]. Tokyo: Japanese Urological Association; 2019. Available from:https:\/\/www.urol.or.jp\/lib\/files\/other\/guideline\/29_hinyoukigann.pdf"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20210314"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.04.003"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.04.015"}],"container-title":["BJUI Compass"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bco2.70082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:46:12Z","timestamp":1759938372000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1002\/bco2.70082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/bco2.70082"],"URL":"https:\/\/doi.org\/10.1002\/bco2.70082","archive":["Portico"],"relation":{},"ISSN":["2688-4526","2688-4526"],"issn-type":[{"value":"2688-4526","type":"print"},{"value":"2688-4526","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70082"}}